ALLO
Allogene Therapeutics Inc

3,350
Mkt Cap
$467.44M
Volume
2.53M
52W High
$2.32
52W Low
$0.8621
PE Ratio
-2.12
ALLO Fundamentals
Price
$2.16
Prev Close
$2.08
Open
$2.10
50D MA
$1.62
Beta
1.55
Avg. Volume
6.32M
EPS (Annual)
-$1.32
P/B
1.47
Rev/Employee
$96.07
$213.23
Loading...
Loading...
News
all
press releases
Allogene Therapeutics, Inc. $ALLO Shares Acquired by Aberdeen Group plc
Aberdeen Group plc boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 82.4% during the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Allogene Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·2d ago
News Placeholder
Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission
Allogene Therapeutics (NASDAQ:ALLO) Chief Medical Officer Zach Roberts said the company expects to report initial data in April from its ALPHA3 study, a frontline consolidation trial evaluating its...
MarketBeat·6d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen
Wall Street Zen cut Allogene Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·10d ago
News Placeholder
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and McKesson (MCK) have performed compared to their sector so far this year.
Zacks·13d ago
News Placeholder
Rapid Innovation is Reshaping Oncology: Stocks in Focus
Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.
Zacks·19d ago
News Placeholder
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) CEO Sells 95,269 Shares of Stock
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) CEO David Chang sold 95,269 shares of the business's stock in a transaction on Monday, February 2nd. The stock was sold at an average price...
MarketBeat·19d ago
News Placeholder
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Zacks·29d ago
News Placeholder
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) EVP Sells 26,269 Shares of Stock
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) EVP Zachary Roberts sold 26,269 shares of the company's stock in a transaction dated Wednesday, January 21st. The stock was sold at an...
MarketBeat·1mo ago
News Placeholder
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Zacks·2mo ago
<
1
2
...
>

Latest ALLO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.